HOME >> BIOLOGY >> NEWS
New anti-inflammatory strategy for cancer therapy identified by UCSD researchers

A new strategy for cancer therapy, which converts the tumor-promoting effect of the immune system's inflammatory response into a cancer-killing outcome, is suggested in research findings by investigators at the University of California, San Diego (UCSD) School of Medicine.

The findings provide new insight into the immune system's response to inflammation, the connection between inflammation and malignancy, and how the delicate balance between cancer promotion and inhibition can be manipulated in the patient's favor, according to the study's senior author, Michael Karin, Ph.D., UCSD professor of pharmacology, American Cancer Society Research Professor, and a member of the Rebecca and John Moores UCSD Cancer Center.

The studies in mice with colon or breast cancer showed that cancer metastasis, the growth of malignant tumors beyond the original site, was halted with inhibition of either one of two naturally occurring substances, a pro-inflammatory protein called nuclear factor-kappa B (NF-kB) or an inflammatory mediator called tumor necrosis factor alpha (TNFα). The result, published in the September 20, 2004 issue of the journal Cancer Cell, was increased effectiveness of a cancer-killing protein called TNF-related apoptosis-inducing ligand (TRAIL), leading to a decrease in cancer cells and increase in the life span of tumor-bearing mice.

The study's first author, Jun-Li Luo, M.D., Ph.D., a member of the Karin team in the UCSD Laboratory of Gene Regulation and Signal Transduction, explained that normally, inflammation associated with malignancy activates NF-kB, TNFα and TRAIL, all at the same time. However, NF-kB has the upper hand, and with TNFα, stimulates tumor growth faster than TRAIL can inhibit it.

"Our results suggest that is it possible to use NF-kB or TNFα inhibitors to prevent inflammation-induced tumor growth, thus destroying their advantage, and allowing TRAIL to tip the balance in its favor,"
'"/>

Contact: Sue Pondrom
spondrom@ucsd.edu
619-543-6163
University of California - San Diego
20-Sep-2004


Page: 1 2 3 4

Related biology news :

1. Anti-cancer agent built from anti-inflammatory drug
2. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
3. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
4. The anti-inflammatory effect of apoptotic bodies
5. Herb used to treat migraine headaches could be used to develop new anti-inflammatory drugs
6. MetaPhore reports general anti-inflammatory surface treatment for biomedical materials
7. Common anti-inflammatory drug rescues low-growth fetuses in mouse study
8. A novel, safer strategy for regulating gene expression
9. European common frog found to use novel mating strategy
10. Promising hospital anti-infection strategy probably wont work, study shows
11. Parasitic cowbirds thrive with a less ruthless strategy than cuckoos

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/31/2019)... ... 2019 , ... FileWave, the multi-platform endpoint management solution for ... version 13.1. The new version extends FileWave’s mobile device management features on the ... functionality. Version 13.1 builds on FileWave’s version 13 that was released in early ...
(Date:5/26/2019)... ... May 24, 2019 , ... Zolgensma (Novartis, AveXis), an AAV-delivered ... approved for clinical use in the United States by the Food and Drug Administration ... approved to treat inherited genetic disorders in the United States and the second-ever approved ...
(Date:5/22/2019)... ... May 22, 2019 , ... Leak Detection Associates (LDA), the ... the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries’ is excited to announce ... Ltd has been signed. The agreement will grant exclusive rights for IPP ...
Breaking Biology News(10 mins):
(Date:5/14/2019)... LA JOLLA, Calif. (PRWEB) , ... May 14, 2019 , ... ... announces an office expansion, effectively doubling its space from 2,500 to 5,000 square feet. ... SneakPeek Early Gender DNA tests ,” says Gateway Genomics CEO, Chris Jacob. “The ...
(Date:5/7/2019)... , ... May 06, 2019 , ... ... resource for the growing number of repositories being asked to store cellular products ... to the team of contributors who are world leaders, who have shared their ...
(Date:5/4/2019)... ... May 03, 2019 , ... Diopsys ... Diopsys® ffERG/Photopic Negative Response vision test, a new full field electroretinography ... is estimated that 6.3 million Americans will have glaucoma, with black Americans having ...
(Date:5/2/2019)... (PRWEB) , ... April 30, 2019 , ... The centuries ... industrial scale macro breweries to local craft breweries, and even home brewing clubs scattered ... complex chemical and biological processes, that when mastered can produce a superb product. Students ...
Breaking Biology Technology:
Cached News: